Myeloid Therapeutics, a clinical-stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic epithelial tumors. MT-302 is the Company’s lead development candidate for in vivo immune cell programming and delivers TROP2-targeting RNA chimeric antigen receptors that express selectively within myeloid cells.
Ronald Vale, PhD, is the lead UCSF inventor of the medical technology Myeloid is advancing.